International Studies of Infarct Survival

The International Studies of Infarct Survival (ISIS) were four randomized controlled trials of several drugs for treating suspected acute myocardial infarction ("heart attack"). More than 134,000 patients from over 20 countries took part in four large simple trials between 1981 and 1993, coordinated from Oxford, England.[1][2]

ISIS-1

The First International Study of Infarct Survival (ISIS-1) was a placebo-controlled trial of the beta-blocker atenolol. It recruited 16,027 patients and was completed in 1985.[3]

ISIS-2

The Second International Study of Infarct Survival (ISIS-2) was a 2×2 factorial placebo-controlled trial of aspirin and the thrombolytic drug streptokinase. It recruited 17,187 patients and was completed in 1988.[4]

ISIS-3

The Third International Study of Infarct Survival (ISIS-3) was a 3×2 factorial trial that compared the three thrombolytic drugs streptokinase, tissue plasminogen activator (tPA) and anistreplase to each other, and also compared the anticoagulant heparin to no heparin. All patients were also given aspirin. It recruited 41,299 patients and was completed in 1991.[5]

ISIS-4

The Fourth International Study of Infarct Survival (ISIS-4) was a 2×2×2 factorial placebo-controlled trial of the angiotensin-converting enzyme inhibitor (ACE inhibitor) captopril, isosorbide mononitrate and magnesium sulphate. It recruited 58,050 patients and was completed in 1993.[6]

See also

References

  1. ↑ Hennekens, Charles H. (1998), "Trials of Thrombolytic Therapy: the International Studies of Infarct Survival Experience", Journal of Interventional Cardiology 11: 1, doi:10.1111/j.1540-8183.1998.tb00089.x
  2. ↑ Hennekens, Charles H.; Skerrett, P.J. (2005), "International Studies of Infarct Survival (ISIS)", Encyclopedia of Biostatistics, doi:10.1002/0470011815.b2a01031
  3. ↑ ISIS-1 (Second International Study of lnfarct Survival) Collaborative Group (1986), "Randomised trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction: ISIS-1", The Lancet 328 (8498): 57–66, doi:10.1016/S0140-6736(86)91607-7
  4. ↑ ISIS-2 (Second International Study of lnfarct Survival) Collaborative Group (1988), "Randomised Trial of Intravenous Streptokinase, Oral Aspirin, Both, or Neither Among 17 187 Cases of Suspected Acute Myocardial Infarction: ISIS-2", The Lancet 332 (8607): 349–360, doi:10.1016/S0140-6736(88)92833-4
  5. ↑ ISIS-3 (Third International Study of lnfarct Survival) Collaborative Group (1992), "ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction", The Lancet 339 (8796): 753–770, doi:10.1016/0140-6736(92)91893-D
  6. ↑ ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group (1995), "ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction", The Lancet 345 (8951): 669–682, doi:10.1016/S0140-6736(95)90865-X
This article is issued from Wikipedia - version of the Wednesday, May 21, 2014. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.